Chris Francis - 26 Feb 2026 Form 4 Insider Report for Wave Life Sciences Ltd. (WVE)

Role
SVP, Corporate Development, Head of Emerging Areas
Signature
/s/ Chris Francis
Issuer symbol
WVE
Transactions as of
26 Feb 2026
Net transactions value
-$357,673
Form type
4
Filing time
27 Feb 2026, 21:00:03 UTC
Previous filing
11 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Francis Chris SVP, Corporate Development, Head of Emerging Areas C/O WAVE LIFE SCIENCES LTD.,, 733 CONCORD AVE., CAMBRIDGE /s/ Chris Francis 27 Feb 2026 0001657709

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction WVE Ordinary Shares Options Exercise $69,273 +17,900 +29% $3.87 79,767 26 Feb 2026 Direct F1
transaction WVE Ordinary Shares Sale $270,183 -17,900 -22% $15.09 61,867 26 Feb 2026 Direct F1, F4
transaction WVE Ordinary Shares Options Exercise $72,646 +15,294 +25% $4.75 77,161 26 Feb 2026 Direct F1
transaction WVE Ordinary Shares Sale $229,410 -15,294 -20% $15.00 61,867 26 Feb 2026 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction WVE Share Option (right to buy) Options Exercise $0 -17,900 -11% $0.000000 143,200 26 Feb 2026 Ordinary Shares 17,900 $3.87 Direct F2
transaction WVE Share Option (right to buy) Options Exercise $0 -15,294 -20% $0.000000 61,175 26 Feb 2026 Ordinary Shares 15,294 $4.75 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 5, 2025.
F2 The option vests as to 25% of the shares on February 5, 2025, and vests as to an additional 6.25% of the shares quarterly thereafter until February 5, 2028.
F3 The option vests as to 25% of the shares on February 17, 2024 and vests as to an additional 6.25% of the shares quarterly thereafter until February 17, 2027.
F4 The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $15.00 to $15.10 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

Remarks:

SVP, Corporate Development, Head of Emerging Areas